Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    A blood test for antibodies will show if you have been exposed to hepatitis C.HIV treatment has particular benefits for people with HIV and hepatitis...

    From: Factsheets

    Information level Level 2
  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance

    AbbVie could have charged a premium for its broader, faster cure. Its choice to go cheap will make Mavyret a huge bargain relative to Gilead's drugs for many patients. Payers will likely seize on that. The major PBMs have purposefully held off on announcing which HCV drugs they'll cover next year. Gilead will have to offer very large discounts or expect to lose market share.

    07 August 2017 | Bloomberg
  • Direct-acting antivirals successfully treating hepatitis C, says Public Health England

    Public Health England (PHE) is urging the public to get tested for hepatitis C after its latest figures revealed a fall in deaths from the disease, which it attributed to the introduction of direct-acting antiviral (DAA) therapy. PHE’s annual report, published on 28 July 2017, estimated that around 200,000 people in the UK are unknowingly living with chronic hepatitis C, but it said that “revolutionary treatments” can successfully treat the disease in the vast majority of cases, with the best results in the earlier stages of the disease.

    02 August 2017 | Pharmaceutical Journal
  • Australia leads the world in hepatitis C treatment – what's behind its success?

    The key to universal access was the Australian government’s capacity to negotiate much lower drug prices than in other high-income countries, following strong advocacy from the hepatitis C sector. For instance, Australia paid an estimated ten-fold lower price per patient treated in 2016 than did Germany.

    31 July 2017 | The Conversation AU
  • Substantial fall in Hepatitis C rates in Canberra's jail with new treatments

    Justice Minister Shane Rattenbury on Friday released new figures showing how new drugs for the virus had helped reduce the number of Hepatitis C-positive inmates from 30% of the prison population in 2010 down to just three per cent this year.

    31 July 2017 | The Canberra Times
  • Hepatitis C patients unable to get drugs due to funding problems

    The treatment of hundreds of patients with hepatitis C with potentially lifesaving drugs has been abruptly halted due to funding problems. The national hepatitis C programme has told hospitals not to make any further applications for funding support for patients until treatment numbers are “realigned”.

    31 July 2017 | Irish Times
  • From chronic to cured: could Australia be the first country in the world to eliminate hep C?

    Australia is on track to eliminate hepatitis C by 2026, a new report released by the Kirby Institute on World Hepatitis Day shows.

    28 July 2017 | Kirby Institute
  • Australian NSP Survey National Data Report 2012 – 2016

    Nationally, the proportion of respondents who reported recent (last 12 months) initiation of HCV treatment was low and stable at 1-3% between 2011-2015, but increased significantly to 22% in 2016, with substantial increases observed in all jurisdictions.

    04 July 2017 | Kirby Institute
  • Charity calls for new focus to combat Hep C infections in Scotland

    A charity has called for greater efforts to eliminate Hepatitis C (HCV) from Scotland. There are about 37,000 people living with the virus - but campaigners say as many again are undiagnosed.

    27 June 2017 | BBC
  • Swiss hepatitis C sufferers to get full access to expensive drug

    The Federal Office of Public Health has announced that it will make the hepatitis C drug Zepatier available to all patients from July 1. The 12-week treatment costs CHF31,000 ($31,952) per patient and was previously only available to those with an advanced form of the disease.

    26 June 2017 | swissinfo.ch
  • European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes

    Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Vosevi®, an investigational, once-daily, single tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients.

    26 June 2017 | Gilead press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.